Article
Risk of malignancy in cytologically indeterminate thyroid nodules harboring thyroid stimulating hormone receptor mutations.
Frontiers in endocrinology - 1 Jan 2022
Whitmer Dorota, Phay John E, Holt Shelby, O'Donnell Benjamin, Nguyen Jay, Joseph Dennis, Chi Anthony, Wu Shuyang, Hao Yangyang, Huang Jing, Klopper Joshua P, Kloos Richard T, Kennedy Giulia C, Shin Joyce
Abstract excerpt
Objectives: To evaluate the frequency and risk of malignancy of TSHRpI568T mutations discovered in indeterminate thyroid nodules (ITN) within the Veracyte CLIA laboratory undergoing Afirma® Genomic Sequencing Classifier (GSC) testing, and to evaluate a broader cohort of TSHR variants and their categorization as Afirma GSC benign (GSC-B) or suspicious (GSC-S). Finally, we seek to assess the risk of malignancy...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.